Time filter

Source Type

Takeda T.,Osaka Cancer Immuno Chemotherapy Center
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2013

We treated 226 patients with advanced or recurrent colorectal cancer using hyperthermia or immunotherapy between July 2005 and September 2012. Clinical benefit (complete response [CR], partial response [PR], and long stable disease [SD] for more than 6 months) was observed in 30 patients (13.3%), including CR in 5 patients. The effective rate of immunotherapy increased from 14.3% to 16.1% using hyperthermia. The effective rate of hyperthermia was 3.9%. Of the 30 effectively treated patients, liver metastases disappeared in 2 patients treated with hyperthermia alone, and lung metastases disappeared in 2 patients treated with immunotherapy alone. In the remaining 26 effectively treated patients, multiple metastases were observed in solid organs. Both hyperthermia and immunotherapy were administered and were found to be effective in the treatment of patients with advanced or recurrent colorectal cancer.


Takeda T.,Osaka Cancer Immuno Chemotherapy Center
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2011

We already informed that a combination therapy of hyperthermia and activated lymphocytes therapy reduced the tumor growth and lung metastasis synergistically in mice model. In this study we treated mice inoculated LLC tumors with hyperthermia or molecular target drugs (erlotinib 25 mg/kg/day and sorafenib 10 mg/kg/day). Both of hyperthermia and molecular target therapy reduced not only tumor growth but also lung metastasis. And a combination therapy of hyperthermia and molecular target therapy reduced more of the tumor growth and lung metastasis synergistically. The expression of HER2 and VEGFR was reduced by hyperthermia and molecular target drugs. Apoptosis was enhanced by hyperthermia and molecular target drugs synergistically.


Takeda T.,Osaka Cancer Immuno Chemotherapy Center
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2013

We treated 172 patients with advanced or recurrent breast cancer using hyperthermia or immunotherapy between July 2005 and September 2012. In these patients, standard therapy showed no results, or it was refused. Clinical benefit( complete response [CR], partial response[PR], and long stable disease [SD] for more than 6 months) was observed in 30 patients( 17.4%), including CR in 5 patients. The effective rate of immunotherapy increased from 7.7% to 26.0% using hyperthermia. The effective rate of hyperthermia was only 5.1%. The standard therapy had not been altered in 23 of the 30 patients in whom clinical benefit was observed. Thus, immunotherapy or hyperthermia had benefited these 23 patients. Of the 23 effectively treated patients, skin or regional lymph node metastases disappeared in 3 patients treated with hyperthermia alone, and lung metastases disappeared and carcinomatous pleuritis improved in 1 patient treated with immunotherapy alone. In the remaining 19 effectively treated patients, multiple metastases were observed in important solid organs such as the liver, lung, bone, and brain. Combined hyperthermia and immunotherapy was used to treat these 19 patients to good effect.


Takeda H.,Osaka Cancer Immuno Chemotherapy Center
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2011

We treated 1, 225 advanced or recurrent cancer patients with hyperthermia or immunotherapy (2005/7-2010/12). We had 174 (14.7%)clinical benefit cases (CR, PR and long SD) including 32 complete response (CR) cases. CASE 1: A 63-year-old male, rectal cancer, post operative recurrence with MRSA abscess located in abdomen. He was treated with dendritic cell therapy and hyperthermia. He showed a CR. CASE 2: A 62-year-old female, ovarian cancer, post operative recurrence. She was treated with standard chemotherapy, but she showed a PD. Then she was treated with dendritic cell therapy and hyperthermia. She showed a CR. CASE 3: A 46-year-old female, lung cancer, postoperative recurrence. She was treated with standard chemotherapy and molecular target therapy, but she showed a PD. Then she was treated with dendritic cell therapy and hyperthermia. She showed a CR.


Takeda T.,Osaka Cancer Immuno Chemotherapy Center
Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2012

We treated 168 advanced or recurrent breast cancer patients with hyperthermia or immunotherapy (2005/7-2011/12). In these cases, standard therapy showed no effect or was refused. Clinical benefit( complete response: CR, partial response, and long stable disease) was observed in 26 cases; CR occurred in 4 cases. The effective rate of immunotherapy increased from 9.1% to 23.9% using hyperthermia. Both hyperthermia and immunotherapy needed to be used together to be effective in 20 cases with distant metastases to solid organs.


PubMed | Osaka Cancer Immuno Chemotherapy Center
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2014

We treated 1,939 patients with advanced or recurrent cancer using hyperthermia and or immunotherapy between July 2005 and November 2013. Standard therapy showed no effect or was refused by these patients. There were 309(15.9%)patients who experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months), including 52 CR cases. The effective rate of immunotherapy increased from 9.9%to 19.1%using hyperthermia. The effective rate for patients with hyperthermia-alone was 3.6%, and skin and regional lymph node metastases disappeared. Immunotherapy alone was effective for liver or lung metastases. Combined hyperthermia and immunotherapy had a beneficial effect on multiple metastases observed in important plural solid organs. Ovarian cancer had the highest effective rate (25.0%), followed by prostate cancer.


PubMed | Osaka Cancer Immuno Chemotherapy Center
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2014

We treated 74 patients with advanced or recurrent head and neck cancer using hyperthermia and/or immunotherapy between July 2005 and November 2013. Standard therapy showed no effect or was refused by these patients. Fifteen(21.4%) patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months), including 4 CR cases. Hyperthermia alone was effective for one patient only. A combination of dendritic cell therapy and hyperthermia was beneficial for the remaining 14 patients. One patient was effectively treated with cetuximab, and lymphocytes and dendritic cell therapy.


PubMed | Osaka Cancer Immuno Chemotherapy Center
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2014

We treated 116 advanced or recurrent ovarian cancer and 102 uterine cancer patients with hyperthermia and/or immunotherapy(2005/7-2013/11). Of these, 63, 31, and 8 patients had cervical cancer, endometrial cancer, and uterine sarcoma, respectively. Standard therapy showed no effect or was refused by these patients. Twenty-nine(25.0%)ovarian cancer patients experienced a clinical benefit(complete response[CR], partial response[PR], and long-term stable disease[SD], >6 months). The effective rate of a combination of therapies including activated lymphocyte therapy, dendritic cell therapy, and hyperthermia was 47.5%. Thirteen(12.7%)uterine cancer patients experienced a clinical benefit. The effective rates for cervical cancer, endometrial cancer, and uterine sarcoma were 7.9%, 22.5%, and 12.5%, respectively. Both hyperthermia and immunotherapy were administered to successfully treat these patients.


PubMed | Osaka Cancer Immuno Chemotherapy Center
Type: Journal Article | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2016

We treated 19 cancer patients with cancer types other than melanoma and lung cancer with immune checkpoint inhibitors, between June 2015 and April 2016. We administered nivolumab at 2-3mg/kg bw every 2-3 weeks. One patient received 14 doses, 5 received 6 doses, 3 received 5 doses, 3 received 4 doses, and 3 received 3 doses. Three remarkably effective responses were seen in cases of pancreatic cancer, esophageal cancer, and brain malignant lymphoma. In every effective case, dendritic cell therapy was administered prior to nivolumab.


PubMed | Osaka Cancer Immuno Chemotherapy Center
Type: Case Reports | Journal: Gan to kagaku ryoho. Cancer & chemotherapy | Year: 2011

We treated 984 advanced or recurrent cancer patients with hyperthermia or immunotherapy (2005/7-2009/12). We have 137 clinical benefit cases (CR, PR and long SD) including 22 complete response (CR) cases. Effective rates of immunotherapy increased from 9.8% to 17.8% using hyperthermia. In the cases of ovarian cancer, head and neck cancer, lung cancer, prostatic cancer, gastric cancer, thyroid cancer and breast cancer, all confirmed high effective rates with hyperthermic immunotherapy.

Loading Osaka Cancer Immuno Chemotherapy Center collaborators
Loading Osaka Cancer Immuno Chemotherapy Center collaborators